About the Company
Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.
Employees
69
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MGTA News
Stifel starts Dianthus at buy, cites market potential of lead drug
The investment firm set its price target for the stock at $44. Dianthus merged with Magenta Therapeutics last year.
Dianthus Therapeutics (DNTH) Price Target Increased by 22.22% to 35.53
Dianthus Therapeutics Background Information (This description is provided by the company.) magenta therapeutics is a biotechnology company harnessing the power of stem cell science to ...
Dianthus Therapeutics Inc (DNTH)
On Wednesday, Stifel initiated coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and a price target of $44.00. The firm's positive outlook is anchored on ...
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript February 28, 2024 G1 Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.27.
Third Rock Ventures GP IV, L.P.'s Net Worth
Inc., Relay Therapeutics, Inc., and Magenta Therapeutics, Inc.. Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to ...
Kintara Therapeutics Inc KTRA
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Ovid Therapeutics Inc OVID
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
EFTR eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product ...
Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments
VistaGen Therapeutics, Inc. (NASDAQ:VTGN), established in 1998 and headquartered in South San Francisco, California, is ...
Q4 2023 Intellia Therapeutics Inc Earnings Call
Ian Karp; SVP, IR and Corporate Communications; Intellia Therapeutics Inc John Leonard; President & CEO; Intellia Therapeutics Inc David Lebwohl; Chief Medical Officer; Intellia Therapeutics Inc ...
Dianthus Therapeutics Inc (DNTH)
Benzinga - by Lisa Levin, Benzinga Editor. Gainers Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) shares gained 35.8% to $21.69 in pre-market trading. Crinetics said Once-daily ...
Loading the latest forecasts...